ANIX News and Press, Anixa Biosciences Inc. From 04/06/22

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022 PR Newswire SAN JOSE, Calif. , April 6, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the...

Biotechnology company Anixa Biosciences (NASDAQ:ANIX +1.6%) initiated a phase 1 trial evaluating its CAR-T therapy in ovarian cancer. The early-stage trial will be held at Moffitt Cancer Center and will evaluate the safety and efficacy of Anixa's therapy in patients with ovarian cancer. ...

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center PR Newswire SAN JOSE, Calif. , March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on ...

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC PR Newswire SAN JOSE, Calif. , March 17, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focuse...

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Preclinical work for the prophylactic vaccine, invented and developed at Cleveland Clinic, is ongoing with support from the National Cancer Institute's PREVENT Program PR Newswire SAN JOSE, Calif...

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor Anixa's compound may be five times more potent than the protease inhibitor in Pfizer's PAXLOVID™ at inhibiting Mpro, the main protease of SARS-CoV-2 PR Newswire S...

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference PR Newswire SAN JOSE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (N...

Anixa Biosciences (NASDAQ:ANIX) announces the results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19. ANIX shares up 2.2% premarket at $3.20. The data indicate that the compounds in development should be effective agains...

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant Compounds also anticipated to be effective against the Delta variant PR Newswire SAN JOSE, Calif. and STUTTGART, Germany , Dec. 7,...

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study - Cleveland Clinic conducting Phase 1 trial - PR Newswire SAN JOSE, Calif. and CLEVELAND , Oct. 26, 202...